Jefferies Financial Group Inc. Invests $757,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

Error: Response status code does not indicate success: 500 (Internal Server Error).

Jefferies Financial Group Inc. bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,200 shares of the company's stock, valued at approximately $757,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. FMR LLC increased its position in Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after buying an additional 21,133 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after acquiring an additional 6,600 shares during the last quarter. Hood River Capital Management LLC raised its stake in Krystal Biotech by 2.1% in the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after acquiring an additional 10,622 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares during the last quarter. Finally, Soleus Capital Management L.P. boosted its position in Krystal Biotech by 65.2% during the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after purchasing an additional 141,400 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KRYS. Bank of America dropped their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Guggenheim cut their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. Citigroup restated a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday. Finally, Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Tuesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $210.22.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the sale, the insider directly owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 49,800 shares of company stock valued at $7,487,943 over the last three months. 13.70% of the stock is currently owned by corporate insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $0.10 on Thursday, reaching $136.10. 320,029 shares of the stock were exchanged, compared to its average volume of 418,876. The firm has a market cap of $3.94 billion, a PE ratio of 27.64 and a beta of 0.70. The firm's 50 day moving average is $141.71 and its 200-day moving average is $155.45. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. On average, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).